Drug
BMN 673
BMN 673 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_2
1
20%
Ph early_phase_1
1
20%
Ph phase_1
3
60%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (20.0%)
Phase 13 (60.0%)
Phase 21 (20.0%)
Trials by Status
withdrawn120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
completedearly_phase_1
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02316834
withdrawnphase_2
A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer
NCT02127151
completedphase_1
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
NCT01989546
completedphase_1
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
NCT01399840
completedphase_1
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
NCT01776437
Clinical Trials (5)
Showing 5 of 5 trials
NCT02316834Early Phase 1
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02127151Phase 2
A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer
NCT01989546Phase 1
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
NCT01399840Phase 1
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
NCT01776437Phase 1
Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5